As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >


4, rue Pierre Fontaine – Genopole Campus 3

Andrey Pichugin: CEO & CSO
Web Site >
FABMID - entreprise génopolitaine FABMID - entreprise génopolitaine

Shaker#Industrial Biotech

  • Cell therapy
  • Gene therapy
  • Non-viral vectorBooster
  • Cell transfection
  • CAR-T cells
  • Bioproduction

Field of Activity

We develop an in vitro manufactured targeted DNA vector to improve the efficiency of therapeutic cell transfection and to reduce the cost of gene-based therapies.


Fabmid has been incorporated in 2020 with the aim of providing novel skills and experience in the development of cell & gene therapies.
Andrey PICHUGIN (PhD, former leader of a public research lab and Founder of Fabmid SAS) developed a method to produce the first circular vector DNA molecules covalently bound with delivery vehicles of choice that target the vector to cellular nucleus.

Fabmid SAS develops safe and efficient solutions for the growing markets of cell & gene therapies. The company aims to ensure the efficient production of CAR-T-cells for helping millions of patients heal from solid and blood cancers.

Fabmid’s products: (1) circular DNA molecules covalently bound with aptamers for targeted vector delivery into cell nucleus and (2) technological platform for the vector production.


  • Biopharma developing cell or gene therapy.
  • Academic laboratories and/or biotech companies experimenting in the field of oncology, immunology, cell&gene therapy, virology…


  • Further information

    Our competitive advantages:

    • Scalable production on a GMP-compliant technological platform, which belongs to emerging cell-free technologies for the generation of synthetic DNA vectors;
    • Transportation and storage of degradation-resistant vector is compatible with flexible logistics schemes;
    • Highest safety features of the vector include a low error-rate in the DNA sequences, no innate immune response against the vector and prevention of integration into the patient’s genome;
    • Clinical application of the modular “lego-like” vector can be designed for repetitive administrations and persistent transgene expression in dividing cells of patients;
    • Economic models may be implemented at an affordable cost for CAR-T cells treatment of cancers and for other gene therapies.

    2 Patents

    A cutting-edge technology for numerous applications, a very large market and a complementary team.

    Innovation Assets:
    A robust technology, highly valuable for clinical application and scalable for industrial production.

Genopole’s Companies

#Industrial Biotech

In same field

The VERY Food Co

Activity of research, sale, production, distribution and marketing of all unregulated food and agri-food products.

STH Biotech - Genopole's company

STH Biotech

STH BIOTECH is developing an innovative cannabis-based process for the reliable and sustainable production of active compounds for the well-being and healthcare sectors.

Synovance - entreprise généopolitaine


Synovance has developed a revolutionary synthetic genomics platform for the conception of robust industrial bioproduction strains.

Altar - entreprise génopolitaine - intégre le groupe Ginko Bioworks


Ginkgo Bioworks is a specialist in the conception and operation of automated fluidic continuous culture systems for adaptive laboratory evolution and the development of microbial strains for industry.

Yposkesi - Genopole's Company


YposKesi is the first French company to develop and manufacture gene and cell therapy products for rare diseases.

Watchfrog Laboratory - Genopole's company


WatchFrog markets in vivo biotechnological solutions for environmental risk assessment and the evaluation of the therapeutic, toxic or pollutant potential of all types of chemical, cosmetic or pharmaceutical compounds.

Pharming - Genopole's company - Logo 2021


Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.

Global Bioenergies - entreprise génopolitaine - logo 2022

Global Bioenergies

Global Bioenergies is developing a process to convert renewable resources into hydrocarbons through fermentation.

ABOLIS - entreprise génopolitaine

Abolis Biotechnologies

Abolis develops custom-order microorganisms able to produce molecules of interest via fermentation for the health, nutrition, chemistry and cosmetics sectors.

View all >
With the support from
Région île de France